MindImmune Therapeutics
Manufacturing · Rhode Island, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
130 Flagg Rd, Kingston, Rhode Island, 02...Phone Number
(401) 225-4612Website
www.mindimmune.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About MindImmune Therapeutics
MindImmune Therapeutics is a biotechnology company developing products that target the immunological drivers of neurodegenerative disease. Its lead program, MITI-101, is designed to block the harmful recruitment of peripheral immune cells into the brain in patients with Alzheimers disease and other neurodegenerative conditions.Explore more
MindImmune Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MindImmune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if MindImmune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on MindImmune Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once MindImmune Therapeutics has new funding data
Product Launch: Get notified when MindImmune Therapeutics launches new products
MindImmune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if MindImmune Therapeutics is spiking on competitors!
Click to see if MindImmune Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at MindImmune Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at MindImmune Therapeutics
Find more new buyers
Compare Similar Companies to MindImmune Therapeutics
Compare insights from companies similar to MindImmune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$6.6M
11-50
Private
-
-
DE
Darren EngersSenior Director of Medicinal Chemistry, Research Assistant Professor of Pharmacology
<$5M
1-10
Private
-
2011
Mark KlevenSenior Vice President, Scientific Operations, Chief Operating Officer
Company Profile Activity
Activity Insights
MindImmune Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MindImmune Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MindImmune Therapeutics.
MindImmune Therapeutics financials insights
Gather financial insights about MindImmune Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Angel/Seed
$500K
2017
Unspecified
$250K
2021
Debt
$57K
2025
Series A
$30M
2026
Unspecified
$5M
MindImmune Therapeutics Tech Stack
A closer look at the technologies used by MindImmune Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
Funding
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MindImmune Therapeutics
Sign Up For FreeTo access detailed company insights
MindImmune Therapeutics is a biotechnology company developing products that target the immunological drivers of neurodegenerative disease. Its lead program, MITI-101, is designed to block the harmful recruitment of peripheral immune cells into the brain in patients with Alzheimers disease and other neurodegenerative conditions.... Read More
